Prognostic and Diagnostic Value of Biomarkers and Cardiac Functional Parameters in Patients With Chronic Heart Failure

Prognostic and Diagnostic Value of Serial Biomarker Measurements, Echocardiographic Techniques and Cardiopulmonary Function Tests in Patients With Chronic Heart Failure.

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT02776384

Enrollment

1000

Registered

2016-05-18

Start date

2015-12-31

Completion date

Unknown

Last updated

2016-05-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Heart Failure

Keywords

Heart Failure, Biomarkers, Echocardiography, Cardiopulmonary Function Tests

Brief summary

The study aims to investigate whether disease progression in patients with chronic heart failure (CHF) can be assessed by new biomarkers, and determine their diagnostic value. The study also intends to describe comparison of echocardiography with cardiopulmonary function test in CHF patients, and relating these cardiac functional parameters to clinical outcome.

Interventions

OTHERObservational study

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Age ≥18 years * with symptoms and signs in NYHA Ⅱ\ Ⅳ * with cardiac structural changes confirmed by echocardiography

Exclusion criteria

* with other severe diseases combined and will be alive for less than 12 months * hard to participate in the investigation or accept the follow-up visits * pregnant or lactating women * during the acute phase of ST-elevation acute myocardial infarction, stroke, severe infection and other critical conditions

Design outcomes

Primary

Measure	Time frame	Description
main adverse cardiovascular and cerebrovascular events, MACCE	10 years	MACCE includes all-cause mortality, cardiovascular mortality, nonfatal myocardial infarction, nonfatal stroke, target lesion revascularization and HF rehospitalization
cardiovascular mortality	10 years	—

Secondary

Measure	Time frame	Description
new stroke	10 years	—
heart failure rehospitalization	10 years	—
all-cause mortality	10 years	—
worsening of renal function	10 years	either an increase of 0.3 mg/dl in serum creatinine or a 20% decrease in eGFR compared with baseline
quality of life	10 years	described in quality of life scores
new myocardial infarction	10 years	—

Countries

China

Contacts

Primary ContactRong Tao, Doctor

rongtao@hotmail.com

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026